Mentioned On
Episode Mentions
Pharma and BioTech Daily · May 7, 2026
Bayer's $2.4B Perfuse Deal Shakes Up Eye Care | Pharma and Biotech Daily
“Halted diabetic macular edema program to focus on rare diseases with higher returns and less competition”
Ophthalmology Portfolio ExpansionAI-Driven Drug Development CommercializationGLP-1 Agonist Obesity Treatment Competition
View Analysis